Gaining control of persistent corneal epithelial defects using AMT and a pressure patch

(Image credit: AdobeStock/Nattle)

A new therapeutic approach that combines eyelid pressure patching with the application of decellularized, dehydrated pure amniotic membrane basement membrane (AMBM), a type of amniotic membrane tissue (AMT), was highly successful and safe for healing persistent corneal epithelial defects,¹ according to Kyle Linsey, MD, who is from the Cornea Service, Clearwater Eye and Laser Center, Clearwater, FL, and HCA Florida Bayonet Point Hospital, University of South Florida, Tampa.

Managing persistent corneal epithelial defects can be tricky, and, according to Linsey, typically consists of treatments such as frequent lubrication, immunomodulators, steroids, autologous serum or platelet-rich plasma tears, bandage contact lens, punctal occlusion, and in more advanced disease, pressure patching, epithelial debridement, scleral contact lenses, cenegermin, and AMT.^2-5

AMT offers a number of advantages to patients that includes rapid re-epithelialization of the persistent corneal epithelial defects in cases refractory to treatment,^6-8 by addressing the ocular surface inflammation,^9,10 at rates of re-epithelialization of 45.5% to 74.7%, independent of ulcer etiology.^11,12 The treatment does not transfer viable stem cells¹³ but “supports damaged tissue, protects and shields defects from further degeneration or breakdown from external factors and promotes re-cellularization,¹⁴” he explained.

In addition, AMT stimulates proliferation and migration of limbal stem cells, suppresses neo-angiogenesis, inflammation, and scarring, contributes to AMT’s ability to support the healing of ocular surface disease¹⁵ and physically acts as a substrate for epithelial cell growth.^16-18

Multilayer AMT has been proposed for treating deep neurotrophic corneal ulcers¹⁹ and is more effective than autologous serum at healing corneal ulcers resulting from herpetic neurotrophic keratitis.²⁰ Finally, it retards infection.

Retrospective findings

In his retrospective study, Linsey analyzed 144 eyes treated with either a single-layer or three-layer decellularized AMBA (Biovance 3L Ocular; Verséa Ophthalmics, Inc.) combined with a 24-hour eyelid pressure patch; 90% were treated with a single layer of AMBM and 10% with three layers of AMBM.

In the single-layer group, Linsey reported, all cases healed completely and the AMBM dissolved. In the three-layer group, all cases had improvements in the corneal staining; however, the AMBM did not dissolve in 20% to 30% of cases. No patients reported pain, discomfort, or infection.

This study found that combining eyelid pressure patching with AMT is a safe and effective approach for healing persistent corneal epithelial defects.

“AMT promotes epithelial cell proliferation, reduces inflammation and neuropathic pain, and limits scar formation.²¹ AMT can act as a mechanical barrier to protect the ocular surface, prevent evaporation and dryness, and maintain a stable tear film while serving as a scaffold for donor–recipient cell migration and integration.²¹ The integration of an eyelid pressure patch with dehydrated, decellularized AMBM treatment for advanced ocular surface disease leads to accelerated corneal healing and increased patient comfort,” Linsey concluded.

References

1. Linsey K. Use of an eyelid pressure patch concomitantly with a decellularized dehydrated amniotic membrane for ocular surface disease management. Ophthalmol Ther. 2025;14:573–584. https://doi.org/10.1007/s40123-025-01094-2

2. Katzman LR, Jeng BH. Management strategies for persistent epithelial defects of the cornea. Saudi J Ophthalmol. 2014;28:168–72.

3. Ljubimov AV, Saghizadeh M. Progress in corneal wound healing. Prog Retin Eye Res. 2015;49:17–45.

4. Rodríguez Calvo-de-Mora M, Domínguez-Ruiz C, Barrero-Sojo F, et al. Autologous versus allogeneic versus umbilical cord sera for the treatment of severe dry eye disease: a double-blind randomized clinical trial. Acta Ophthalmol. 2022;100:e396–408.

5. Sánchez-González JM, Alonso-Aliste F, Borroni D, et al. Plasma rich in growth factors (PRGF) in transepithelial photorefractive keratectomy (TPRK). J Clin Med. 2021;10:1939.

6. Fernandes M, Sridhar MS, Sangwan VS, et al. Amniotic membrane transplantation for ocular surface reconstruction. Cornea. 2005;24:643–53.

7. Prabhasawat P, Tesavibul N, Komolsuradej W. Single and multilayer amniotic membrane transplantation for persistent corneal epithelial defect with and without stromal thinning and perforation. Br J Ophthalmol. 2001;85:1455–63.

8. Letko E, Stechschulte SU, Kenyon KR, et al. Amniotic membrane inlay and overlay grafting for corneal epithelial defects and stromal ulcers. Arch Ophthalmol. 2001;119:659–63.

9. Sheha H, Liang L, Li J, Tseng SC. Sutureless amniotic membrane transplantation for severe bacterial keratitis. Cornea. 2009;28:1118–23.

10. Sheha H, Tighe S, Cheng AM, Tseng SC. A stepping stone in treating dendritic keratitis. Am J Ophthalmol Case Rep. 2017;7:55–8.

11. Sell S, de la Presa M, Thakur S, Eslani M, Jeffrey J, Sheppard JD, Holland EJ, Cheung AY. Comparison of persistent epithelial defect treatment with sutureless cryopreserved and dehydrated amniotic membrane. Am J Ophthalmol. 2023;251:32–42.

12. Lacorzana J, Campos A, Brocal-Sánchez M, et al. Visual acuity and number of amniotic membrane layers as indicators of efficacy in amniotic membrane transplantation for corneal ulcers: a multicenter study. J Clin Med. 2021;10:3234.

13. Füst A, Pállinger E, Stündl A, et al. Both freshly prepared and frozen-stored amniotic membrane cells express the complement inhibitor CD59. Sci World J. 2012;2012: 815615.

14. Walkden A. Amniotic membrane transplantation in ophthalmology: an updated perspective. Clin Ophthalmol. 2020;22:2057–72.

15. Pogozhykh O, Hofmann N, Gryshkov O, et al. Repeated freezing procedures preserve structural and functional properties of amniotic membrane for application in ophthalmology. Int J Mol Sci. 2020;21:4029.

16. Dua HS. Amniotic membrane transplantation. Br J Ophthalmol. 1999;83:748–52.

17. Burman S, Tejwani S, Vemuganti GK, et al. Ophthalmic applications of preserved human amniotic membrane: a review of current indications. Cell Tissue Bank. 2004;5:161–75.

18. Thiex NW, Chames MC, Loch-Caruso RK. Tissue-specific cytokine release from human extra-placental membranes stimulated by lipopolysaccharide in a two-compartment tissue culture system. Reprod Biol Endocrinol. 2009;7:117.

19. Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol. 2014;8:571–9.

20. Turkoglu E, Celik E, Alagoz G. A comparison of the efficacy of autologous serum eye drops with amniotic membrane transplantation in neurotrophic keratitis. Semin Ophthalmol. 2014;29:119–26.

21. Tighe S, Mead OG, Lee A, Tseng SCG. Basic science review of birth tissue uses in ophthalmology. Taiwan J Ophthalmol. 2020;10:3–12.